Cargando…

Treatment options for acute myeloid leukemia patients aged <60 years

Treatment of acute myeloid leukemia (AML) has changed over the last few years, after the discovery of new drugs selectively targeting AML blasts. Although 3/7 remains the standard of care for most AML patients, several new targeted agents (such as FLT3 inhibitors, CPX-351, gemtuzumab ozogamicin, BCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Visani, Giuseppe, Chiarucci, Martina, Paolasini, Sara, Loscocco, Federica, Isidori, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581198/
https://www.ncbi.nlm.nih.gov/pubmed/36276074
http://dx.doi.org/10.3389/fonc.2022.897220